Kidney cancer: Single nucleotide polymorphisms in mRCC-is their time up?

Nat Rev Urol. 2015 Aug;12(8):424-6. doi: 10.1038/nrurol.2015.149. Epub 2015 Jun 30.

Authors

Benoit Beuselinck¹, Jessica Zucman-Rossi²

Affiliations

¹ Department of General Medical Oncology and Laboratory for Experimental Oncology, University Hospitals Leuven, KU Leuven, Herestraat 49, B-3000 Leuven, Belgium.
² Inserm, UMR-1162, Génomique fonctionnelle des tumeurs solides, Institut Universitaire d'Hématologie (IUH), Rue Juliette Dodu 27, F-75010 Paris, France.

PMID: 26123039
DOI: 10.1038/nrurol.2015.149

No abstract available

Publication types

Comment

MeSH terms

Antineoplastic Agents / therapeutic use*
Carcinoma, Renal Cell / drug therapy*
Cytochrome P-450 CYP3A / genetics*
Female
Humans
Indoles / therapeutic use*
Kidney Neoplasms / drug therapy*
Male
Polymorphism, Single Nucleotide*
Protein Kinase Inhibitors / therapeutic use*
Pyrroles / therapeutic use*

Substances

Antineoplastic Agents
Indoles
Protein Kinase Inhibitors
Pyrroles
Cytochrome P-450 CYP3A